论文信息 - Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (RE - 字舞流文

Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (RE

R. Winterhalder | A. Mueller | H. Hawle | M. Borner | R. Cathomas | P. Bohanes | S. Gillessen | C. Rothermundt | A. Templeton | S. Hayoz | A. Pedrazzini | S. Anchisi | R. Moos | T. Wehrhahn | S. Stoll | H. Burmeister | C. Schaer | A. Lladó | A. Fuhrer | Urs Sebastian Huber-Tribolet